Application Value of Neoadjuvant Targeted Therapy in Patients with EGFR-mutant
Resectable Lung Adenocarcinoma.
10.3779/j.issn.1009-3419.2025.106.18
- Author:
Shijie HUANG
1
;
Mengying FAN
2
;
Kaiming PENG
3
;
Wanpu YAN
2
;
Boyang CHEN
1
;
Wu WANG
1
;
Tianbao YANG
1
;
Keneng CHEN
4
;
Mingqiang KANG
3
;
Jinbiao XIE
1
Author Information
1. Department I of Cardiothoracic Surgery, The Affiliated Hospital of Putian University, Putian 351100, China.
2. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department I of Thoracic Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China.
3. Department II of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou 350000, China.
4. State Key Laboratory of Molecular Oncology, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department I of Thoracic Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China.
- Publication Type:English Abstract
- Keywords:
Epidermal growth factor receptor;
Lung neoplasms;
Major pathologic response;
Neoadjuvant targeted therapy
- MeSH:
Humans;
ErbB Receptors/metabolism*;
Male;
Female;
Middle Aged;
Adenocarcinoma of Lung/surgery*;
Neoadjuvant Therapy;
Lung Neoplasms/surgery*;
Aged;
Retrospective Studies;
Mutation;
Adult
- From:
Chinese Journal of Lung Cancer
2025;28(7):487-496
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:The proportion of patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations is relatively high in China. However, these patients currently lack significant benefits from available neoadjuvant treatment options. This study aims to explore the potential application value of neoadjuvant targeted therapy by evaluating its efficacy and safety in patients with EGFR-mutant resectable lung adenocarcinoma.
METHODS:A multicenter retrospective study was used to analyze the treatment effect of patients with stage IIA-IIIB EGFR-mutant lung adenocarcinoma who underwent surgical resection after receiving neoadjuvant targeted therapy from July 2019 to October 2024.
RESULTS:A total of 24 patients with EGFR-mutant lung adenocarcinoma from three centers were included in this study. All patients successfully underwent surgery and achieved R0 resection of 100.0%. The objective response rate (ORR) was 83.3% (20/24) . The major pathologic response (MPR) rate was 37.5% (9/24), with 2 patients (8.3%) achieving pathological complete response (pCR). During neoadjuvant therapy, 13 out of 24 patients (54.2%) experienced adverse events of grade 1-2, with no occurrences of ≥ grade 3. The most common treatment-related adverse events were rash (n=4, 16.7%), mouth sores (n=2, 8.3%), and diarrhea (n=2, 8.3%). The median follow-up time was 33.0 months, no deaths occurred in all patients, and the overall survival (OS) rate was 100.0%. The 1-year disease-free survival (DFS) rate was 91.1%, and the 2-year DFS rate remained at 86.2%.
CONCLUSIONS:The application of neoadjuvant targeted therapy in patients with EGFR-mutant resectable lung adenocarcinoma is safe and feasible, and is expected to become a highly promising neoadjuvant treatment option for the patients with EGFR-mutant lung adenocarcinoma.
